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Both anaemia and allogenic red blood cell transfusion are common and 
potentially harmful in patients admitted to the intensive care unit. Whilst 
intravenous iron may decrease anaemia and RBC transfusion requirement, safety 
and efficacy in critically ill patients is uncertain.  
Methods 
The multicentre, randomized, placebo-controlled, blinded, Intravenous Iron or 
Placebo for Anaemia in Intensive Care (IRONMAN) study was designed to test 
the hypothesis that, in anaemic, critically ill patients admitted to the intensive 
care unit, early administration of intravenous iron, compared with placebo, 
reduces allogenic red blood cell transfusion and increases haemoglobin to 
hospital discharge.  
Results 
Of 140 patients enrolled, 70 were assigned to intravenous iron and 70 to 
placebo. The iron group received 97 red blood cell units versus 136 red blood 
cell unit in the placebo group, incidence rate ratio 0.71 [95% confidence interval 
(0.43-1.18) P=0.19].  Overall, median haemoglobin at hospital discharge was 
significantly higher in the intravenous iron group compared with the placebo 
group (107 (IQR 97-115) vs. 100 g/L (IQR 89-111),, P=0.02). There was no 
significant difference between the groups in any safety outcome.  
Conclusions 
In patients admitted to the intensive care unit who were anaemic, intravenous 




cell transfusion at hospital discharge. Patients who received intravenous iron 
had a significantly higher haemoglobin at hospital discharge.  
The trial was registered at www.anzctr.org.au as # ACTRN12612001249842. 
 




Anaemia is extremely common in patients admitted to the intensive care unit 
(ICU) and is the most common indication for allogenic red blood cell (RBC) 
transfusion even when adherence with transfusion guidelines is high[1, 2]. Both 
anaemia and RBC transfusion may be harmful to critically ill patients. Anaemia is 
an independent risk factor for mortality and major morbidity in patients 
undergoing major surgery and in general ICU patients; RBC transfusion is 
associated with mortality, nosocomial infection, multi-organ dysfunction 
syndrome and the acute respiratory distress syndrome (ARDS) in patients 
treated in an ICU [3-6].  
Progressive anaemia and subsequent RBC transfusion are predictable at the time 
of ICU admission[7]. In selected patients, novel interventions implemented 
shortly after ICU admission could reduce the incidence and severity of anaemia, 
the need for RBC transfusion, and therefore the burden of associated morbidity 
and mortality. Intravenous (IV) iron decreases both the severity of anaemia and 
incidence of RBC transfusion in non-critically ill patients [8]. However, there is a 
theoretical risk of causing or worsening infection and older preparations are 
associated with anaphylactic reactions [8-10]. High quality safety and efficacy 
data for IV iron in the critical care setting are lacking.  
We designed the multicentre Intravenous Iron or Placebo for Anaemia in 
Intensive Care (IRONMAN) RCT to test the hypothesis that, in critically ill 
patients admitted to the ICU who are anaemic, early administration of IV ferric 
carboxymaltose, compared with placebo, reduces the mean number of RBC units 





Patients, Materials and Methods 
Study Design and Oversight 
Between 20 June 2013 and 6 June 2015, we conducted a randomized, placebo-
controlled, blinded trial in four ICUs in Perth, Western Australia. The study 
protocol was registered prospectively on the Australian New Zealand Clinical 
Trials Registry (ANZCTRN12612001249842), was approved by the ethics 
committee at each participating site, and has been published previously[11]. 
Prospective consent was obtained from all participants or their legal surrogates. 
The trial was overseen by an independent Data Safety Monitoring Committee. 
Study drug was supplied by Vifor Pharma which had no other role in the design 
or conduct of the study or analysis and reporting of the results. 
Study Population 
Patients were eligible to participate if they were 18 years of age or older, within 
48 hours of admission to ICU, anticipated to require ICU care beyond the next 
calendar day and had a haemoglobin (Hb) less than 100 g/L at any time in the 
preceding 24 hours. Exclusion criteria included suspected or confirmed severe 
sepsis, a ferritin greater than 1200 ng/ml or transferrin saturation greater than 
50%. A complete list of the exclusion criteria are provided in the supplementary 
appendix.  
Randomization and blinding 
Eligible patients were randomly assigned in a 1:1 ratio to receive either IV iron 
or placebo. The randomization sequence was generated by an online resource 
was stratified according to study centre[12]. Allocation concealment was 
maintained by using permuted block randomisation and sealed, opaque, 
 
 
consecutively numbered envelopes at each study site that had been generated 
centrally by staff unrelated to the study or ICU. Randomisation was to a study 
number. Study medication was then prepared by a clinical nurse or pharmacist 
not involved in the care of the patient. An opaque sleeve covering the study drug 
infusion syringe and giving set was used to maintain blinding of the participants, 
treating, site researchers and data collectors [13]. The adequacy of blinding was 
assessed by conducting a blinding substudy measuring interrater agreement 
between the study intervention actually delivered and the opinion of the 
intervention arm according to the attending clinician using Cohen’s Kappa.  
Study Treatments 
Patients randomized to the IV iron group received 500mg of ferric 
carboxymaltose in 100 ml of 0.9% saline delivered in two consecutive 50ml 
syringes. Details of the study treatment including a photo of the blinding set up 
have been published previously[11]. Patients in the placebo group received 
100ml of 0.9% saline alone. Four days after receiving the initial or subsequent 
dose of study drug, patients remaining in the ICU were assessed for repeat 
dosing. Participants were eligible for redosing if they continued to fulfill the 
study eligibility criteria, including repeated ferritin and transferrin saturation 
parameters and an Hb<100g/L. Assessment for suitability for redosing 
continued until the patient was discharged from the ICU, received four doses of 
study drug or died, whichever occurred first.  
The IV iron formulation was chosen on the basis of data supporting  superiority 
of ferric carboxymaltose at fixed dose compared with an alternate IV iron 
formulation and low reported side effect profile [14, 15]. The ferritin and 
transferrin saturation (TSAT) cutoffs were chosen on the basis of the higher end 
 
 
of the effective reported range (ferritin <1200mn/ml) and lack of interaction 
between TSAT and IV iron on RBC transfusion[8, 16].  
All aspects of patient management, including decision for RBC transfusion and 
ICU discharge, were administered according to local practice and at the direction 
of the treating ICU clinician. There were no RBC transfusion policies in any of the 
participating centres. Open-label IV iron and erythropoiesis-stimulating agents 
were strongly discouraged and use of these agents were a protocol violation.  
Study Outcomes 
The primary study outcome was number of RBC units transfused per patient 
between randomisation and hospital discharge reported according to an 
intention-to-treat analysis. Secondary outcomes included Hb at hospital 
discharge, proportion of patients receiving RBC transfusion, ICU and hospital 
length of stay and mortality and infection. Infection was defined as the 
commencement, escalation or change of IV antibiotics for a confirmed or 
strongly suspected infection and was adjudicated locally by blinded clinical staff. 
Clinically confirmed deep vein thrombosis (DVT) and pulmonary embolism (PE) 
were explicitly collected as SAEs. Bleeding definitions are provided in the 
supplementary appendix. Admission diagnoses were based on acute physiology 
and chronic health evaluation (APACHE) II diagnostic codes. Events were 
deemed to be part of the natural history of the primary disease process or 
expected complications of critical illness were not reported as SAEs unless 
thought to be causally related to the study intervention.  
Statistical Analysis 
All analyses  were conducted on an intention-to-treat basis. No imputation was 
made for missing data. Continuous variables were reported as mean (±SD) or 
 
 
median and interquartile range (IQR), with between group differences analysed 
using Student’s t-test or the Wilcoxon rank-sum test for apparently normal and 
non-normally distributed data respectively. Categorical variables were reported 
as proportion and analysed using the Chi2 test or Fischer exact test as 
appropriate. Data was censored at 60 days after enrolment for Hb level, RBC 
transfusion and vital status. A two-sided P value of 0.05 or less was considered to 
be statistically significant.  All analyses were conducted with Stata Version 14 
StataCorp College Station, TX77845, USA. No interim analyses were planned or 
conducted.  
Although the analyses were conducted according to a previously reported 
statistical analysis plan [13], the number of RBC units was not normally 
distributed and, in conjunction with advice from an independent statistician 
(Centre for Applied Statistics, University of Western Australia), the primary 
outcome has been reported as median and IQR instead of the prespecified mean 
and standard deviation (SD). The data has then been analysed using negative 
binomial regression with incidence-rate ratios reported. This analysis satisfied 
the assumptions as count data with over-dispersion (variance greater than the 
mean). The sample size of 140 participants was based on a baseline mean of four 
RBC transfusions in eligible patients, determined from an observational study 
conducted in one of the participating study sites, with a SD in the intervention 
and control groups of two and a loss to follow-up of 10%[7]. This provided 80% 
power to detect a decrease in the mean number of RBC transfusions of 1 unit at a 
significance level of 5%.  
Additional sensitivity analyses of the primary outcome variable adjusted for 
predefined covariates (enrollment Hb, RBC transfusion prior to enrollment, 
 
 
transferrin saturation, ferritin, soluble transferrin receptor and renal 
replacement therapy) were performed using negative binomial regression for 
count data. The effect of IV iron on incidence-rate ratio of RBC transfusion was 
performed for predefined subgroups including transferrin saturation (<20% or 
≥20%) and ferritin (<200ng/ml or ≥200ng/ml).  
Results 
We enrolled 140 patients, with 70 assigned to IV iron and 70 to placebo. All 
participants received the intervention to which they were randomly allocated 
and all patients were followed up to discharge from index hospitalisation. One 
patient declined consent to ongoing participation at time of ICU discharge but 
consented to data use. Repeat dosing of study drug occurred in 17 patients in the 
IV iron group (15 patients received two doses, three patients received three 
doses) and 26 patients in the placebo group ( 23 patients received two doses, 
three patients received three doses). Seven participants in the IV iron group and 
three participants in the placebo group received non-study-drug IV iron either in 
ICU (n=1) or post-ICU discharge (n=9). There was no missing data for the 
primary or prespecified secondary outcomes (Figure 1). Demographic and 
clinical characteristics at baseline were similar between the groups (Table 1), 
and there was no significant association between perceived and actual study 
group allocation (McNemar’s test chi2 2.37, p=0.12).  
Primary Outcome 
The IV iron group was transfused 97 RBC units versus 136 RBC units in the 
placebo group. The number of RBC units transfused in the ICU was 79 (81%) and 
121 (89%) for the IV iron and placebo groups respectively. The median (IQR) 
RBC transfusion in the IV iron and placebo groups [1 unit (0-2) vs. 1 unit (0-3) 
 
 
P=0.53],  incidence rate ratio (IRR) [0.71 (95% confidence interval (CI) 0.43-
1.18) P=0.19].  (Table 2). There was no significant between-group difference in 
RBC transfusion with the use of multivariable binomial regression adjusting for 
predefined baseline covariates (P=0.77), or according to a per protocol analysis 
(P=0.15). Between-group RBC transfusion was also similar in the predefined 
subgroups (Table 3). RBC transfusion (figure 3) and median Hb (figure 4) by day 
whilst in ICU are provided in the supplementary appendix. 
Secondary Outcomes 
Overall, the median Hb at hospital discharge was significantly higher in the IV 
iron group compared with the placebo group (107 g/L (IQR 97-115) vs. 100 g/L 
(IQR 89-111), P=0.02). The histograms for the Hb on hospital discharge for the 
two groups are provided in the supplementary appendix (figure 2). In a post-hoc 
analysis, the proportion of patients discharged from hospital with an Hb<100g/L 
was significantly lower in the IV iron compared with placebo groups (21/70 
(30%) vs 33/70 (47%), p=0.04). The IV iron and placebo groups had similar 
median lengths of stay in ICU and hospital, and no significant differences in ICU 
and hospital mortality were observed (Table 2).  
Safety 
There was no statistical difference between the iron and placebo groups in 
infection, infection associated with organ failure, or bacteraemia. The number of 
serious adverse events (SAEs) did not differ significantly between groups. There 
were no immediate study-drug-related adverse events in the IV iron group and 
one in the placebo group where shivering post study drug administration was 




In this multicentre randomized trial of patients admitted to the ICU who were 
anaemic, we found that IV iron, compared with placebo, did not result in a 
significant difference in number of RBC units transfused. IV iron did however 
result in a significantly higher Hb concentration at hospital discharge. Safety 
outcomes, specifically mortality, infection, clinically diagnosed venous 
thrombosis and immediate infusion-related adverse events were not 
significantly different in those receiving IV iron compared with placebo.   
Outside of the critical care setting, trials enrolling patients with similar baseline 
Hb and haematinics have shown a significant decrease in RBC transfusion 
associated with IV iron therapy [8]. Although the point estimate for the primary 
outcome in our study favored IV iron, the difference was not significant. One 
possible reason is that IV iron is simply ineffective in patients admitted to the 
ICU due to the modulating effects of severe inflammation on the erythropoietic 
response to IV iron. [17, 18]. Given that the point estimate of the primary 
outcome favors IV iron with a clinically meaningful decrease in incidence rate 
ratio of 0.71, and the statistically significant increase in Hb at hospital discharge 
associated with IV iron, this would appear unlikely. Perhaps more likely is the 
effect of the mean number of RBC units transfused being substantially lower (1.9 
units in the placebo group) than anticipated. Our study was powered to detect a 
one unit reduction from a baseline of four units transfused; the observed 
reduction was 0.5 units. The study was underpowered to detect such a difference 
leading to the possibility of a type II error (see supplementary appendix for a 
power calculation for a future trial of IV iron). 
Whilst our study attempted to identify a cohort of patients at high risk of 
progressive anaemia and subsequent RBC transfusion,  characteristics associated 
 
 
with an erythropoiesis response to IV iron in the critical care setting are poorly 
understood and require further consideration. For example, the relative efficacy 
of IV iron in patients with anaemia at least partly due to absolute iron deficiency, 
compared with anaemia of inflammation alone, remains uncertain, and  
measurement of hepcidin may be of value [17]. Future trials of IV iron in critical 
illness should consider adopting a lower Hb threshold for enrolment, only 
enrolling patients with a longer predicted length of stay, and targeting the 
intervention at those most likely to mount an erythropoeitic response. This 
would have the simultaneous effect of identifying a population at higher risk of 
RBC transfusion and prolonged ICU stay and greater risk of adverse outcomes. 
Pieracci et al conducted an RCT of IV iron sucrose in trauma patients admitted to 
the ICU and found no difference in Hb concentration[19]. In contrast, our study 
found that IV iron resulted in a statistically significant increase in Hb at hospital 
discharge and a greater proportion of patients discharged with an Hb>100g/l, 
although the clinical significance of these findings is uncertain.  
Compared with Pieracci et al, our study used a higher dose of iron, and an 
alternative preparation previously shown to be associated with greater 
erythropoietic response [14]. Our study also enrolled patients at higher risk of 
RBC transfusion (Hb threshold for enrollment 100 g/l vs 120 g/l) and included a 
broader range of critically ill patients, potentially at greater risk of preexisting 
iron deficiency.  
It is plausible that a higher Hb during recovery from critical illness may be of 
clinical benefit, including more rapid functional recovery and decreased LOS. 
Although our study did not find a significant decrease in hospital LOS associated 
with IV iron, the median duration from initiation of IV iron to hospital discharge 
 
 
was 11 days, whereas maximal therapeutic effect may not occur for three to four 
weeks. Whether the observed difference was greater post-discharge, and the 
clinical benefits of a higher Hb in a cohort of patients with a longer estimated 
LOS require further consideration.  
Bateman et al found that moderately severe anaemia at the time of ICU discharge 
was associated with a markedly reduced health-related quality of life score at 
three and six months compared with a non-selected ICU cohort, and that over 
half remained anaemic at six months[20]. Postoperative rehabilitation studies 
suggest that anaemia is associated with fatigue, reduced exercise capacity, 
muscle strength and performance in activities of daily living and may impair 
recovery [21]. Furthermore, Froessler et al,  found that IV iron prior to major 
abdominal surgery was associated with a significant decrease in hospital length 
of stay and a significant increase in Hb at four weeks, suggesting a role for IV iron 
in enhancing recovery[22].  
Our study found no association between IV iron and infection. We defined new 
infection in terms of the commencement, escalation or change of antibiotics. This 
definition was pragmatic, reflective of clinical practice, and assessed by blinded 
clinicians. Future studies may consider blinded adjudication by independent 
experts and powering the study to exclude a clinically important difference in 
infection. 
The formulation and dosing of IV iron in our study resulted in no immediate 
adverse events. Given the lack of data in for IV iron use in ICU, we chose a 
cautious approach to dosing and it is plausible that in future studies, a higher, 
weight-based dosing and/or continued dosing after ICU discharge, may result in 
 
 
a greater response to IV iron. The comparative efficacy of other IV iron 
preparations in the this context remains uncertain.  
Strengths 
Our study has a number of strengths including a pragmatic design, effective 
blinding, administration of the study drug to all participants according to the 
assigned study group,  complete follow up to discharge from index 
hospitalisation and the use of a restrictive RBC transfusion approach 
Limitations 
The data distribution for the primary outcome required a change to the planned 
statistical analysis, adding to the possibility of a type II error. Baseline 
transfusion was lower than planned, reducing the power of our study to detect a 
difference in RBC units. A small proportion of patients received non-study IV 
iron; however, the number were not significantly different between groups and 
did not change the findings when the groups were analysed per protocol. The 
significant increase in Hb at discharge was a secondary outcome and there is a 
risk that this is a chance finding due to multiple testing. However, the point 
estimate for RBC transfusion also favors IV iron, so a false positive result is 
considered less likely. Fewer patients required transfusion for major 
haemorrhage in the IV iron compared with placebo groups, although the 
difference was not statistically significant. Although a differential effect of 
mortality or hospital LOS may affect interpretation of the primary end-point, 
neither were significantly different between groups and so this is considered 
unlikely. Finally, threshold for RBC transfusion was at the discretion of the 
treating clinician and not specified as part of the study. Treating clinicians were 
 
 
however blinded to the study allocation and median Hb prior to transfusion was 
within published guidelines and not significantly different between groups[23]. 
Conclusion 
In patients admitted to the ICU who were anaemic, IV iron compared with 
placebo, did not result in a significant difference in RBC transfusion at hospital 
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Figure 1. Participant Flow 
 
Figure 2. Supplementary Appendix, Histogram of Hb at hospital discharge for IV 
iron and Placebo Groups  
 
Figure 3. Supplementary Appendix, Total RBC units by study day for patients 
remaining in ICU 
 
Figure 4. Supplementary Appendix, Median Hb by study day for patients 
remaining in ICU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
